Department of Medicine, University of Calgary, Calgary, Alta., Canada.
Respiration. 2013;85(1):36-42. doi: 10.1159/000342343. Epub 2012 Nov 13.
Tunneled pleural catheters (TPC) are used in the management of malignant pleural effusions (MPE), but the impact of this palliative procedure on patient quality of life (QoL) has not been well described.
To ascertain the impact of TPCs on symptoms and QoL of patients with recurrent MPE.
Patients with recurrent MPE completed the EORTC QLQ-C30 and LC13 QoL questionnaires at baseline, 2 and 14 weeks; FACIT-TS-G© treatment satisfaction surveys were completed at 14 weeks.
A total of 82 patients were recruited. Thirty-seven patients (37/82, 45%) died prior to their 14-week follow-up appointment. Significant improvements in dyspnea at 2 weeks were demonstrated with both dyspnea scores (LC13 baseline score 64.1, 2-week score 43.7, mean change -20.4, n = 56, p < 0.001; C30 baseline score 78.9, 2-week score 46.6, mean change -32.4, n = 68, p < 0.001), as well as with the MRC score (baseline median score 4, 2-week score 3, n = 70, p < 0.001). Global health status/QoL was also significantly improved at 2 weeks (baseline score 34.1, 2-week score 46.3, mean change 12.3, n = 68, p < 0.001). Improvements in cough, fatigue and all functional scales were noted at 2 weeks. The improvements in dyspnea and global health status/QoL were maintained to 14 weeks in surviving subjects and there was further improvement in the MRC score at 14 weeks. Patients who completed the FACIT-TS-G survey demonstrated overall satisfaction with TPC treatment.
TPCs are associated with a significant improvement in global health status, QoL and dyspnea at the 2-week time point in patients with recurrent MPE.
经皮胸腔导管（TPC）用于恶性胸腔积液（MPE）的管理，但该姑息性手术对患者生活质量（QoL）的影响尚未得到很好的描述。
确定 TPC 对复发性 MPE 患者症状和 QoL 的影响。
复发性 MPE 患者在基线、2 周和 14 周时完成 EORTC QLQ-C30 和 LC13 QoL 问卷；在 14 周时完成 FACIT-TS-G©治疗满意度调查。
共招募了 82 名患者。在 14 周随访预约之前，37 名患者（37/82，45%）死亡。在 2 周时，呼吸困难评分（LC13 基线评分 64.1，2 周评分 43.7，平均变化-20.4，n=56，p<0.001；C30 基线评分 78.9，2 周评分 46.6，平均变化-32.4，n=68，p<0.001）以及 MRC 评分（基线中位数评分 4，2 周评分 3，n=70，p<0.001）均显著改善。2 周时，总体健康状况/QoL 也显著改善（基线评分 34.1，2 周评分 46.3，平均变化 12.3，n=68，p<0.001）。2 周时咳嗽、疲劳和所有功能量表均有改善。在存活患者中，呼吸困难和总体健康状况/QoL 的改善持续到 14 周，MRC 评分在 14 周时进一步改善。完成 FACIT-TS-G 调查的患者对 TPC 治疗总体满意。
在复发性 MPE 患者中，TPC 在 2 周时与总体健康状况、QoL 和呼吸困难的显著改善相关。
